There is no established optimal protocol
This conversation is particularly important for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), as these represent absolute contraindications to the use of products with the thyroid C-cell tumor boxed warning, including semaglutide, liraglutide, dulaglutide, exenatide extended-release, and tirzepatide
: , ,
The research community has made a misstep in its efforts to treat ME/CFS 199 , and some physicians, poorly educated in the aetiology and pathophysiology of the disorder, still advise patients to pursue harmful interventions such as graded exercise therapy and cognitive behavioural therapy, despite the injury that these interventions cause 200 and the fact that they are explicitly not advised as treatments 163,164,166
Your provider reviews your complete medical history, current medications, and comorbidities alongside the renal numbers